High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction

Wynn G Hunter1, Robert W McGarrah2, Jacob P Kelly3

  • 1Department of Medicine, Duke University School of Medicine, Durham, North Carolina.

Insights

High-density lipoprotein particle (HDL-P) subfractions differ between heart failure types and predict adverse outcomes. These findings offer new insights into HDL

Area of Science:

  • Cardiovascular Research
  • Lipid Metabolism
  • Heart Failure Pathophysiology

Background:

  • Circulating high-density lipoprotein particle (HDL-P) subfractions influence atherogenesis, inflammation, and endothelial function, key factors in heart failure (HF) development.
  • Understanding HDL-P subfraction differences is crucial for elucidating HF pathobiology.

Purpose of the Study:

  • To compare plasma HDL-P subfractions between patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).
  • To determine the prognostic significance of HDL-P subfractions in patients with heart failure.

Main Methods:

  • Analysis of 782 HFrEF patients, 1,004 HFpEF patients, and 4,742 controls from the CATHGEN biorepository.
  • Nuclear magnetic resonance-based lipoprotein profiling of plasma samples.
  • Multivariable analysis of covariance and Cox proportional hazards modeling to assess HDL-P subfractions and clinical outcomes.

Main Results:

  • Mean HDL-P size was significantly larger in HFrEF compared to HFpEF and controls (p < 0.0001).
  • Concentrations of small HDL-P and total HDL-P were lower in HFrEF than HFpEF and controls (p ≤ 0.0002).
  • Both total HDL-P and small HDL-P were inversely associated with adverse events in HFrEF and HFpEF patients, independent of clinical covariates.

Conclusions:

  • Significant derangements in HDL-P subfractions exist in heart failure, being more pronounced in HFrEF than HFpEF.
  • These HDL-P subfraction alterations are independently linked to adverse cardiovascular outcomes.
  • The findings may enhance risk stratification and deepen understanding of HDL's role in HF pathophysiology.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
308